JPMorgan Chase Bank, National AssociationGilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Gilead Sciences, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
August 5, 2010Letter Agreement • November 8th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Gilead Sciences, Inc. (“Company”) to JPMorgan Chase Bank, National Association, London Branch (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
EXECUTION VERSIONGilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Gilead Sciences, Inc. (“Company”) to Goldman, Sachs & Co. (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
Attention: Treasurer Telephone No.: (650) 522-5727 Facsimile No.: (650) 522-3000 A/C: 028820868 Ref. No.: SDB1631893036Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Gilead Sciences, Inc. (“Company”) to Goldman, Sachs & Co. (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
August 30, 2010Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
Goldman, Sachs & Co.Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
August 30, 2010Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
Goldman, Sachs & Co.Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
Goldman, Sachs & Co.Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
August 30, 2010Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
August 30, 2010Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
August 5, 2010Letter Agreement • November 8th, 2010 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Gilead Sciences, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for this Transaction.
Goldman, Sachs & Co.Gilead Sciences Inc • November 8th, 2010 • Biological products, (no disgnostic substances)
